Literature DB >> 25841390

Palliative care for patients with locally advanced and metastatic non-small cell lung cancer.

Charles B Simone1, Joshua A Jones2.   

Abstract

Non-small cell lung cancer (NSCLC) often presents at an advanced stage and can result in a significant symptomatic burden. Many patients with advanced NSCLC experience symptoms that include pain, dyspnea, cough, decreased appetite, weight loss, and depression. Early initiation of palliative care for advanced or metastatic NSCLC can reduce symptoms, improve quality of life, and prolong survival. Palliative care interventions by an interdisciplinary team focus on patient and family and address physical symptoms, illness understanding, coping, and psychosocial and spiritual distress. The addition of systemic therapy to best supportive care can further improve quality of life and prolong survival. Thoracic external beam radiation therapy beam radiotherapy is well tolerated and can improve quality of life and relieve symptoms such as hemoptysis, pain, cough, and dyspnea. For central airway obstruction, external beam radiation therapy, endobronchial brachytherapy, Nd:YAG laser therapy, and photodynamic therapy can improve symptoms. Symptomatic lung metastases to the brain, adrenal glands, and liver or compressing or impinging the spinal cord or nerve roots can also result in patient symptoms and can be managed with medical and pharmacologic interventions, radiation therapy, surgery, ablative therapy, and systemic therapy. All healthcare providers treating patients with advanced or metastatic NSCLC should make palliative care a priority by assessing for pain, dyspnea, coping and psychosocial distress, and other symptoms at each patient encounter to reduce patient morbidity, improve quality of life, and potentially prolong survival.

Entities:  

Keywords:  Non-small cell lung cancer (NSCLC); cancer pain; palliative care; quality of life; radiation therapy

Year:  2013        PMID: 25841390     DOI: 10.3978/j.issn.2224-5820.2013.08.02

Source DB:  PubMed          Journal:  Ann Palliat Med        ISSN: 2224-5820


  8 in total

1.  Long-term survival outcomes of video-assisted thoracic surgery for patients with non-small cell lung cancer.

Authors:  Wenlong Shao; Xinguo Xiong; Hanzhang Chen; Jun Liu; Weiqiang Yin; Shuben Li; Xin Xu; Xin Zhang; Jianxing He
Journal:  Chin J Cancer Res       Date:  2014-08       Impact factor: 5.087

2.  Functional impairment, symptom severity, and overall quality of life in patients with advanced lung or colorectal cancer in six European countries: baseline findings from the ACTION study.

Authors:  Mariëtte N Verkissen; Aline De Vleminck; Mogens Groenvold; Lea J Jabbarian; Francesco Bulli; Wilfried Cools; Johannes J M van Delden; Urška Lunder; Guido Miccinesi; Sheila A Payne; Kristian Pollock; Judith A C Rietjens; Luc Deliens
Journal:  Support Care Cancer       Date:  2021-03-19       Impact factor: 3.603

3.  Definitive surgery and intraoperative photodynamic therapy: a prospective study of local control and survival for patients with pleural dissemination of non-small cell lung cancer.

Authors:  Charles B Simone; Keith A Cengel
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2014-03-18

4.  Effect of heated humidified high-flow nasal cannula (HFNC) oxygen therapy in dyspnea patients with advanced cancer, a randomized controlled clinical trial.

Authors:  Zhaoning Xu; Pingping Li; Chi Zhang; Dedong Ma
Journal:  Support Care Cancer       Date:  2022-08-19       Impact factor: 3.359

Review 5.  Photodynamic therapy for lung cancer and malignant pleural mesothelioma.

Authors:  Charles B Simone; Keith A Cengel
Journal:  Semin Oncol       Date:  2014-10-07       Impact factor: 4.929

6.  Morbidity, mortality and long-term outcome of lung cancer resections performed in palliative intent.

Authors:  Emanuel Palade; Jutta Günter; Juan M M Gomez; Ulrich F Wellner; Severin Schmid; Sebastian Wiesemann; Bernward Passlick
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

7.  Lidocaine alleviates cytotoxicity-resistance in lung cancer A549/DDP cells via down-regulation of miR-21.

Authors:  Qing Yang; Zhi Zhang; Haixia Xu; Chuangen Ma
Journal:  Mol Cell Biochem       Date:  2019-01-14       Impact factor: 3.396

Review 8.  The utilization of immunotherapy with radiation therapy in lung cancer: a narrative review.

Authors:  John H Heinzerling; Kathryn F Mileham; Charles B Simone
Journal:  Transl Cancer Res       Date:  2021-05       Impact factor: 0.496

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.